This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Neutralization of SARS-CoV-2 variants by rVSV-ΔG-spike-elicited human sera (preprint)
EuropePMC; 2021.
Preprint
in English
| EuropePMC | ID: ppcovidwho-293181
ABSTRACT
BriLife® (rVSV- ΔG-spike) is a SARS-CoV-2 vaccine candidate based on vesicular stomatitis virus (VSV) platform. We show that sera from BriLife® vaccinees maintain neutralization capacity against alpha, beta, gamma and delta SARS-CoV-2 variants. BriLife® spontaneously-acquired spike mutations, corresponding with key SARS-CoV-2 variants mutations, may contribute to its efficacy against SARS-CoV-2 variants.
Full text:
Available
Collection:
Preprints
Database:
EuropePMC
Topics:
Vaccines
/
Variants
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS